Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TWAV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTaoWeave raises capital via SAFE and debt financing, enters tech partnership with Manako Labs
Filed June 3, 2026 · Period ending May 28, 2026 · ~1 min read
Key Changes
-
high
TaoWeave secured financing through a SAFE (converts to equity later) and TLDA (debt) from Manako Labs, announced June 1. Specific amounts not disclosed, but represents immediate capital infusion with future dilution risk.
Item 7.01, 9.01 verify on EDGAR → -
high
Company signed technology license and distribution agreement with Manako Labs on May 28. Key terms redacted, but suggests commercial partnership for TaoWeave's technology with potential revenue implications.
Item 9.01 - Exhibit 10.1 view on EDGAR → -
medium
TaoWeave issued warrants to Manako Labs as part of financing package. Warrants allow future share purchases at set price, creating potential dilution when exercised but common in startup financing.
Item 3.02, Exhibit 4.1 view on EDGAR → -
medium
Manako Labs agreed to lock-up restrictions (May 29), preventing immediate sale of any equity received. This typically stabilizes share price by preventing sudden selling pressure from new investors.
Item 9.01 - Exhibit 10.3 view on EDGAR →
Summary
TaoWeave announced a multi-faceted transaction with Manako Labs that combines financing and a commercial partnership. The company raised capital through both a SAFE agreement (which will convert to equity in a future financing round) and a term loan, though dollar amounts were not disclosed.
Simultaneously, TaoWeave granted Manako Labs technology licensing and distribution rights, suggesting Manako will help commercialize TaoWeave's products or services. For retail investors, this represents a classic growth-stage financing structure: immediate cash in exchange for future equity dilution, plus warrants that add more potential dilution. The lock-up agreement provides some near-term price protection.
The key question is whether the undisclosed financing amount and the commercial partnership justify the dilution. The redacted terms in the license agreement make it impossible to assess the revenue potential or exclusivity arrangements. Watch for: (1) TaoWeave's next quarterly report, which should reveal the financing amounts and any initial revenue from the Manako partnership, and (2) any subsequent filings that might disclose the redacted commercial terms once confidential treatment expires.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
TaoWeave issued warrants and announced TLDA and SAFE investment via press release on June 1, 2026.
Added in current filing · verify on EDGAR →
In connection with the issuance of the Warrants described in Item 1.01, the Company relied upon the exemption from registration provided by Section 4(a) (2) of the Securities Act and Regulation D promulgated thereunder for transactions not involving a public offering.
TaoWeave issued warrants in a private placement transaction exempt from SEC registration under Section 4(a)(2) and Regulation D. The specific terms of the warrants are referenced in Item 1.01 but not detailed in the provided excerpt. This represents a capital-raising activity that may dilute existing shareholders when warrants are exercised.
Added in current filing · verify on EDGAR →
On June 1, 2026, the Company issued a press release announcing the TLDA and SAFE investment.
The company publicly announced a TLDA (Term Loan and Debt Agreement) and SAFE (Simple Agreement for Future Equity) investment through a press release. These are financing instruments that provide capital to the company, with SAFE typically converting to equity in future financing rounds and TLDA representing debt financing. The specific terms and amounts are not disclosed in the provided excerpt.
Event · Item 7.01 — Regulation FD Disclosure
TaoWeave entered into multiple agreements with Manako Labs including a technology license, distribution deal, lock-up, and SAFE financing.
Added in current filing · verify on EDGAR →
Technology License and Distribution Agreement, dated May 28, 2026, by and between the Company and Manako Labs Ltd.
TaoWeave entered into a technology license and distribution agreement with Manako Labs Ltd. on May 28, 2026. Certain portions of this agreement have been redacted under Regulation S-K. This suggests a potentially significant commercial partnership involving technology rights and distribution arrangements.
Added in current filing · verify on EDGAR →
Simple Agreement for Future Equity, dated May 28, 2026, by and between the Company and Manako Labs Ltd.
TaoWeave issued a Simple Agreement for Future Equity (SAFE) to Manako Labs Ltd. on May 28, 2026, with an accompanying side letter agreement. A SAFE is a financing instrument that converts to equity in future financing rounds, indicating TaoWeave raised capital from Manako Labs with potential future dilution to existing shareholders.
Added in current filing · verify on EDGAR →
Lock-Up Agreement, dated May 29, 2026, by and between the Company and Manako Labs Ltd.
TaoWeave and Manako Labs entered into a lock-up agreement on May 29, 2026. This typically restricts the sale of shares for a specified period, suggesting Manako Labs may be receiving equity and agreeing not to sell immediately, which can provide price stability.
Added in current filing · verify on EDGAR →
Form of Warrant
TaoWeave issued warrants, likely to Manako Labs as part of the overall transaction package. Warrants give the holder the right to purchase shares at a specified price, representing potential future dilution to existing shareholders if exercised.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify